Skip to content
Home/Companies/MedTech/Axellis

Axellis

MedTech·UK·Exited 2022·Held 4yr
Entry
2018
Hold
4yr
Exit
2022

Who owns Axellis?

Axellis was owned by Sobera Capital through Sobera Capital Fund IV (2017 vintage) from 2018 to 2022.

Hand-verified · updated 2026-08-10

Sobera Capital
Investor
Sobera Capital
Sobera Capital Fund IV · 2017 · Secondaries

Key facts

HQUnited Kingdom
SectorMedTech
StatusAcquired
Exit Type
–
Buyer
–
MOIC
–
Exit Year
2022

More from Sobera Capital Fund IV

Other portfolio companies in the same fund.

EffRx Pharmaceuticals
EffRx Pharmaceuticals
Exited 2023
PharmaSwitzerland· 2018
to Abiogen Pharma
M.O.R.E Medical Solutions
Active
MedTechGermany· 2018
Memo Therapeutics
Memo Therapeutics
Exited 2026
BiotechSwitzerland· 2018
to Ipsen
MyoScience
Exited 2019
MedTechUS· 2018
to Pacira BioSciences
Presidio Pharmaceuticals
Active
PharmaUS· 2018
Panoratio
Exited 2021
Data & AnalyticsGermany· 2015

More PE-backed in MedTech

Comparable medtech deals from other GPs.

Acufocus, Inc.
Exited 2023
The Carlyle GroupUS
to Bausch + Lomb
Adicon Holdings Limited
Active
The Carlyle GroupUS
Aesynt
Exited 2016
Francisco PartnersUS
to Omnicell
Alere Medical, Inc.
Active
TA AssociatesUS
Alma Lasers, Ltd.
Alma Lasers, Ltd.
Active
TA AssociatesIsrael
Amedes Group
Active
General AtlanticGermany
Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue